Novo Nordisk says the expiration of its patents for some semaglutide GLP-1 drug treatments in markets like Canada will result ...
The once-a-day semaglutide pill is approved for reducing the risk of heart disease and Type 2 diabetes, the company said in a statement Monday.
Losing weight has officially become more convenient. The popular GLP-1 obesity treatment Wegovy is now available as a once-daily pill. On Monday evening, the Food and Drug Administration approved Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results